|

"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL

RECRUITINGSponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Actively Recruiting
SponsorIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Started2019-10-23
Est. completion2026-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06919393

Summary

It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study;
* Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL;
* Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;
* Participant is willing and able to give informed consent for participation in the study;
* Male or Female, aged \>18 years;
* Availability of clinical data.

Exclusion Criteria:

* Age \< 18 years;
* B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.

Low blast percentage (\<70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;

Conditions2

CancerLeukemia, Lymphoblastic

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.